Sanofi (SNY.US) submits a new indication for its long-acting RSV monoclonal antibody for market approval.
On August 7, the CDE official website announced that Sanofi (SNY.US) has had its new indication application for Nezawa monoclonal antibody injection accepted, with a registration classification of Class 3.1.
On August 7, the CDE official website announced that the application for a new indication of Sanofi's (SNY.US) Nirsevimab injection has been accepted, with a registration classification of Class 3.1. Based on publicly available information and clinical trial progress, the Insight database speculates that this application is aimed at preventing lower respiratory tract infections caused by respiratory syncytial virus (RSV) in infants: specifically, newborns and infants who will soon be born or are born during the second RSV infection season.
Source of the screenshot: CDE official website
Nirsevimab is a single-dose long-acting antibody vaccine jointly developed by Sanofi and AstraZeneca PLC Sponsored ADR, which provides rapid protection through antibodies with just one dose, helping to prevent lower respiratory tract diseases caused by RSV without activating the immune system.
Related Articles
SINOPEC CORP (00386) spent approximately 5.6054 million yuan on August 7 to repurchase 1.1 million A shares.
Non-opioid painkiller developer Latigo (LTGO.US) aims to take advantage of the biotechnology IPO "tailwind"! Issuing price set at $18 per share, planning to raise $346 million.
Hong Kong digital marketing service provider Boshite Technology (POCH.US) raises its IPO pricing to $5-7, increasing the fundraising amount by 33% to $38 million.
SINOPEC CORP (00386) spent approximately 5.6054 million yuan on August 7 to repurchase 1.1 million A shares.
Non-opioid painkiller developer Latigo (LTGO.US) aims to take advantage of the biotechnology IPO "tailwind"! Issuing price set at $18 per share, planning to raise $346 million.
Hong Kong digital marketing service provider Boshite Technology (POCH.US) raises its IPO pricing to $5-7, increasing the fundraising amount by 33% to $38 million.
RECOMMEND
